Open AccessRecent Advances in the Management of Patients with Relapsed/Refractory Follicular Lymphoma
Author(s) -
Georgios Pongas,
Bruce D. Cheson
Publication year - 2021
Publication title -
blood and lymphatic cancer
Language(s) - English
Resource type - Journals
ISSN - 1179-9889
DOI - 10.2147/blctt.s267569
Subject(s) - follicular lymphoma , refractory (planetary science) , medicine , lymphoma , follicular phase , oncology , intensive care medicine , biology , astrobiology
Advanced follicular lymphoma (FL) often relapses after front-line chemoimmunotherapy, and many patients will eventually require subsequent therapy. In 2021, two new therapies were granted approval by the Food and Drug Administration (FDA), including the PI3Kδ inhibitor umbralisib and the chimeric antigen receptor-T-cell therapy (CAR-T) axicabtagene ciloleucel. Herein, we present the latest advances in the management of FL, discussing the recently approved therapies in the relapsed and refractory (R/R) setting and various new therapeutic modalities that have the potential to change the treatment landscape and natural history of R/R FL.